Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT01631552 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

515

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Esophageal Cancer
Hepatocellular Carcinoma
Non-small Cell Lung Cancer
Small Cell Lung Cancer
Ovarian Epithelial Cancer
Carcinoma Breast Stage IV
Hormone-refractory Prostate Cancer
Head and Neck Cancers- Squamous Cell
Renal Cell Cancer
Urinary Bladder Neoplasms
Cervical Cancer
Endometrial Cancer
Glioblastoma Multiforme
Triple Negative Breast Cancer
Pancreatic Cancer

Interventions

DRUG: Sacituzumab Govitecan-hziy (SG)

Sponsor

Gilead Sciences